Drugs

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on VIBATIV(R) (telavancin) for the Treatment of Nosocomial Pneumonia

SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/29/12 -- Theravance, Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and ...

Genetic Technologies Provides Update on Board and Management Changes

MELBOURNE, AUSTRALIA: MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/29/12 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today the appointment of Dr. Mal Brandon to the position of Chairman. In addition, ...

Xylitol Canada Inc. Financial Results for Three and Nine Months Ended September 30, 2012

TORONTO, ONTARIO: TORONTO, ONTARIO -- (Marketwire) -- 11/27/12 -- Xylitol Canada Inc. ("Xylitol Canada", or the "Company") (TSX VENTURE: XYL) today announces that it has released its financial and ...

Sirona Biochem's Second Skin Lightening Compound Shows Superiority Over Industry Standard in Study

VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/22/12 -- . (TSX VENTURE: SBM)(PINKSHEETS: SRBCF)(FRANKFURT: ZSB), announced today that its second cosmetic compound developed by its subsidiary comp ...

Sirona Biochem's Subsidiary TFChem Winner of Acclaimed Innovation Award in France

VANCOUVER, BRITISH COLUMBIA: Winners Selected for Patent Strength, Competitive Advantage and Growth Potential ...

Sunshine Heart Receives Unconditional FDA Approval for C-Pulse(R) System's U.S. Pivotal Trial

EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA: EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA -- (Marketwire) -- 11/20/12 -- Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC), a global medical device company focused on innovative technologies for moderate to ...

Sirona Biochem's Skin Lightener Compound Seven Times More Effective Than Popular Commercial Lightener in Study

VANCOUVER, BRITISH COLUMBIA: Compound viability in $9 billion market established; Product development takes next steps ...

Boston Therapeutics' Newly Appointed Chief Operating Officer Invests $625,000 in the Company's S-1 Financial Offering

MANCHESTER, NH: MANCHESTER, NH -- (Marketwire) -- 11/14/12 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to ...

Sirona Biochem Announces Stock Options Exercise Price Revision

VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/13/12 -- Sirona Biochem Corp. (TSX VENTURE: SBM)(PINKSHEETS: SRBCF)(FRANKFURT: ZSB) announced today it has revised the exercise price of incentive s ...

SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th

FOSTER CITY, CA: FOSTER CITY, CA -- (Marketwire) -- 11/12/12 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business u ...